Open AccessAstragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease
Author(s) -
Xiaoyu Liang,
Fashui Hong,
ShuLong Yang
Publication year - 2021
Publication title -
diabetes, metabolic syndrome and obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.853
H-Index - 43
ISSN - 1178-7007
DOI - 10.2147/dmso.s304817
Subject(s) - oxidative stress , fatty liver , inflammation , apoptosis , alcoholic liver disease , disease , medicine , liver injury , chemistry , biochemistry , cirrhosis
Non-alcoholic fatty liver disease (NAFLD) is the main form of chronic liver disease in the world. Astragaloside IV (ASIV) has been tested in experimental models of different diseases. The purpose of this study was to evaluate the effect and protective mechanism of ASIV on NAFLD.